Semaglutide Treatment in Type 1 Diabetes

NCT06909006 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide helps adults with type 1 diabetes and obesity manage their weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 122 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-10 · est. completion 2028-06

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT06909006 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.

Treatments tested

Semaglutide 2.4mg also known as Active semaglutide Drug

The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator
Semaglutide placebo also known as Placebo semaglutide Drug

Visually identical and same label as the active comparator intervention

Main thing measured	Body weight
Sponsor	Nordsjaellands Hospital
Conditions studied	Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance, Semaglutide, Lipidomics, Metabolomics, Weight Loss, Glycemic Control for Diabetes Mellitus
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06909006 ↗